Home   Therapy   Physicians   Network   Workshops   Contact   Member-Login   Facebook  

  • News 2010

  • News 2009

  • News 2008

  • News 2007

  • News 2006

  • News 2005

  • News 2004

  • News 2003

  • Newsletter?

    Click here!

    Lipolysis News

    21.12.08 08:53

    Lipolysis today - "Dr. Franz" reviews the current status of research

    The Medical Director of the NETWORK, MR Dr. Franz Hasengschwandtner, reviews the current status of research...

    Lipolysis today
    Lipolyse heute – eine Bestandsaufnahme von "Dr. Franz"
    The Medical Director of the NETWORK, MR Dr. Franz Hasengschwandtner, reviews the current status of research...

    As a therapy, injection lipolysis (IL) has developed enormously since 2003 thanks to the activities of our members and the work of several universities.
    This review has the aim of briefly summarizing the current state of the art.

    1. The protocol developed by NETWORK-Lipolysis has been continuously upgraded.
      1. The list of contra-indications has been adjusted each year in line with the latest insights; the patient anamnesis form is now in Version 8.
      1. The list of indications is acquiring clearer form, thanks also to the feedback from our members. Today, we can describe the indications for liploysis as follows:
        1. Aesthetic indications that produce particularly good results:
          • Double chin
          • Jowls
          • Belly
          • Love handles
          • Inner side of the legs
          • Dorsal bulges
        1. Aesthetic indications with variable results:
          • Cheeks
          • Nasolabial groove
          • Axillary folds
          • Saddle Bags
          • Upper arms
          • Knee
        1. Cellulite 3-step therapy
        2. Lipomas
        3. Pseudogynaecomasty (lipomasty)
        4. Skin tautening
      1. The NETWORK maintains a hotline for dealing with urgent questions and also a complications management system, even through our rate of complications is very low (0.00175%).
      2. 3 publications on the issue of safety based on retrospective studies by NETWORK members and by the NETWORK itself have already been published. A further publication is currently in preparation.
      3. The compound developed by the NETWORK has proved its efficacy. The side-effects have been reduced.
    1. Publications and studies
      1. Publications
        A total of 12 publications have appeared in prestigious medical journals in the course of the last 3 years. An updated list of the publications is available at the following link.
      1. Studies
        1. On the topic of lipoma, a team at Bochum University around senior physician Dr. Hoffmann and Dr. Falk Bechara has already produced 2 publications; a 3rd publication is due to appear in the near future.
        2. It should be noted at this point that there is 1 study published by Prof. Daisy Kopera of Graz which comes to the conclusion that lipolysis does not work. Both at the NETWORK and in university circles there are serious doubts concerning this study – not because the outcome doesn’t suit us but because in our opinion the study design was such that it would inevitably produce redundant results.
        3. In contrast to this, an as yet unpublished study by Prof. Schuller-Petrovich of Vienna states that the active substances, polyenylphosphatidylcholin (PPC) and desoxycholic acid (DOC), massively destroy all the cells. Also in the case of this study, we suspect that the design does not meet the necessary standards. However, it will only be possible to say more once the study has been published.
        4. In an animal study involving New Zealand rabbits, S.Klein, L. Prantl et al. of Regensburg University have demonstrated that Lipostabil can reduce fat. The results of the study have already been published. (Note: PPC and DOC are the correct chemical abbreviatians, PC and DC are often used in literature and in US)
        5. In cooperation with the Institute for Pharmaceutical Technology (Dr. T. Blunk, A.Seitz), S.Klein, L.Prantl et al investigated both the individual substances and the combination of active substances contained in Lipostabil on live fat cells in vitro. The study is already completed, and a publication with the results has been submitted. Without wishing to anticipate the results, it can be stated that for the first time they furnish evidence-based proof of efficacy.
        6. A study on the subject of cellulite by Prof. Nor El-Din of Cairo University is currently in progress. The goal of the study is to further improve the results of the IL 3-step therapy through combination treatments.
        7. Already completed and due for publication in the near future is a study by Prof. Hanan Elkahki of Ain Shams University in Egypt on the topic of skin tautening using IL
        8. 2 further studies have not yet started but have either been already approved by the Ethics Commissions or are due for assessment by the responsible Ethics Commission. One, under Prof. Roy de Vita of Rome University, relates to the treatment of buffalo hump in HIV patients, the other, conducted by Regensburg University under the leadership of Dr. Lukas Prantl, investigates the treatment of smaller cushions of fat in vivo.
    1. Summary of the current state of the art
      Based on evidence, we can state today that the cell membrane of adipocytes is destroyed by certain substances and substance combinations; we can also state what those substances are. It should, however, be noted that by no means all of the processes that take place have already undergone evidence-based analysis. We can see this from the feedback of our members concerning unusual results. These take the form of questions on specific results to which we are not yet able to provide answers. I would like to present these open questions at this point, also as a way of showing that a great deal of work still awaits the NETWORK and its members and that there are still many mysteries waiting to be unravelled:
      1. If the cell membrane is dissolved, why do different patients respond at different speeds – some already after only 1 treatment, others only after 2-5? If no reduction in volume can be determined after the 1st treatment, is this because the fat that has been released simply stays put in the region until a certain limit (dosage?) is exceeded that triggers the impulse for the loose fat to be transported away. The question also arises concerning the extent to which the substances employed, as well as destroying the membrane, also have an influence on removal of the fat through detergent effects.
      2. Sensitivity to pain varies from patient to patient. Nevertheless, the pain must be kept within a certain limit that the patient is well able to tolerate. In a very small number of patients, however, this limit is exceeded, and we have to ask ourselves why that is the case and what we can do to prevent it.
      3. A further issue is the non-responder rate. Our goal must be to reduce this figure to a minimum. To this end, we need unequivocal answers to the question as to what factors are responsible for non-response: the experience of the treating physician, the choice of patient, mental or physiological factors, diagnosis and anamnesis, consistency of the fat, or simply the number of treatments given, i.e. whether these patients really are non-responders or “simply” therapy dropouts.
      4. The process of metabolization is also theoretically understood, but so far there have been no enzymatic studies on the process whatsoever. Such studies could also shed further light on many of the questions raised here.
      5. The search for new combinations of active substances is in full swing. We firmly believe that although the results are already very good, they could be improved still further, either through reduction in the side-effects or through enhanced efficacy.
      6. To what extent the treatment intervals could be shortened through combination therapies is also a subject of discussion within the NETWORK.



    Trainings & Workshops:

    (click on image)

    Phone contact

    +49 -2508-21 59-200

    American NETWORK-Lipolysis

    Please visit our
    US/CAN Website

    Congress Lectures by NETWORK Members

    Canada: CACS 5th Annual Congress

    Short information about the congress
    October 24/25/26, 2008
    Montefiore Club, 1195 Guy, Montreal, QUE
    Topics: Esthetic medicine & surgery
    Lipolysis - Lasers - Fillers
    Botox - Fat transfer - Breast - Facelifts - etc.
    NETWORK director Dr. Franz Hasengschwandt-
    ner will present a lecture about IL - State of the Art.

    Link to the programme


    Click on the picture for the programme

    Intern. Congress in Aesthetic and Anti-aging Medicine & MediSpa

    Dubai, UAE - Nov 29 to Dec 1, 2008

    This Conference will discuss the latest cutting edge treatments for “Patient’s Global Management”, in the combination of aesthetic and anti-aging medicine.
    NETWORK member Dr. Angelo-Khattar will give a lecture about Injection Lipolysis.

    Interventional Cosmetics

    NETWORK members Dr. Ines Verner, (Israel) and Mark Palmer (UK) after their lectures on Peels and Injection Lipolysis at the "Interventional Cosmetics" Conference of The Royal Society of Medicine, London, Feb. 25th, 2008. Co-Founder of NETWORK-Lipolysis Ulrich Bunzek (GER) welcomed both at the NETWORK Information booth.

       © 2004-2016 by Lichtblick GmbH    Imprint